This site is intended for healthcare professionals only
This site is intended for healthcare professionals only
Imperial College Healthcare NHS Trust, London, England
Professor Jane Apperley is the Chair of Haemato-Oncology at Hammersmith Hospital, London, the Clinical Director for Clinical Haematology at the Imperial College Healthcare NHS Trust, London, and the Chair of the Centre of Haematology at the Imperial College, London.
Professor Apperley’s research interests include the biology and management of CML, including the use of tyrosine kinase inhibitors, and the effects of hematological diseases and their treatment on fertility, pregnancy and foetal outcomes. She has been a member of the European LeukemiaNet (ELN) CML Working Party since 2004 and has been involved with the ELN Consensus Guidelines since the first recommendations in 2006. She has also been a member of the UK National Cancer Research Institute CML study group for >20 years, and played a key role in the development of the current British Committee For Standards In Haematology guidelines.
Hospital da Luz, Lisbon, Portugal
Professor Antonio Almeida is Head of Department at Hospital da Luz, Lisbon, Portugal, and head of the Hemato-oncology Diagnostic Laboratory at the Portuguese Institute of Oncology in Lisbon.
Professor Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a hematology epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS. He has written book chapters and is the author of more than 60 articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.
University of Turin, Turin, Italy
Professor Giuseppe Saglio is a Professor of Hematology and Internal Medicine at the University of Turin, where he is additionally coordinator of the PhD programme in Medicine and Experimental Therapy. He is also Head of the Division of Hematology at the Mauriziano Hospital, Turin.
Professor Saglio has published more than 500 peer-reviewed articles on molecular pathogenesis of hematological diseases, molecularly targeted therapy and molecular characterization of hematological malignancies.
Hôpital Saint-Louis, Paris, France
Dr Delphine Rea is a physician specialized in Clinical Hematology. She belongs to the University Medical Department of Hematology and Immunology of Saint-Louis University Hospital, Paris, France, where she focuses on the management of patients suffering from myeloid malignancies, especially chronic myeloid leukemia (CML) and rare myeloproliferative disorders.
Dr Rea’s interests centre around clinical haematology. Besides traditional patient care, she is involved in academic and pharma-sponsored clinical trials, translational CML research, and medical education. She is the Vice President of the French Cooperative Group of CML (FI-LMC) and works with several international organizations including the European School of Hematology (ESH), ESH-International Chronic Myeloid Leukemia Foundation, The EuropeanLeukemiaNet, the Society of Hematologic Oncology, and the American Society of Hematology.
SA Pathology, Adelaide, Australia
Associate Professor Sue Branford is Head of the Leukaemia Lab in the Department of Genetics and Molecular Pathology at SA Pathology, Adelaide.
Dr Branford's research is focused on understanding the factors that predict for response to tyrosine kinase inhibitor therapy and the mechanisms of drug resistance. She has expertise in molecular monitoring of the BCR-ABL1 gene for patients with CML. As such she is a major contributor to international collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data.
Imperial College Healthcare NHS Trust, London, England
Professor Jane Apperley is the Chair of Haemato-Oncology at Hammersmith Hospital, London, the Clinical Director for Clinical Haematology at the Imperial College Healthcare NHS Trust, London, and the Chair of the Centre of Haematology at the Imperial College, London.
Professor Apperley’s research interests include the biology and management of CML, including the use of tyrosine kinase inhibitors, and the effects of hematological diseases and their treatment on fertility, pregnancy and foetal outcomes. She has been a member of the European LeukemiaNet (ELN) CML Working Party since 2004 and has been involved with the ELN Consensus Guidelines since the first recommendations in 2006. She has also been a member of the UK National Cancer Research Institute CML study group for >20 years, and played a key role in the development of the current British Committee For Standards In Haematology guidelines.
Hospital da Luz, Lisbon, Portugal
Professor Antonio Almeida is Head of Department at Hospital da Luz, Lisbon, Portugal, and head of the Hemato-oncology Diagnostic Laboratory at the Portuguese Institute of Oncology in Lisbon.
Professor Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a hematology epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS. He has written book chapters and is the author of more than 60 articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.
University of Turin, Turin, Italy
Professor Giuseppe Saglio is a Professor of Hematology and Internal Medicine at the University of Turin, where he is additionally coordinator of the PhD programme in Medicine and Experimental Therapy. He is also Head of the Division of Hematology at the Mauriziano Hospital, Turin.
Professor Saglio has published more than 500 peer-reviewed articles on molecular pathogenesis of hematological diseases, molecularly targeted therapy and molecular characterization of hematological malignancies.
Hôpital Saint-Louis, Paris, France
Dr Delphine Rea is a physician specialized in Clinical Hematology. She belongs to the University Medical Department of Hematology and Immunology of Saint-Louis University Hospital, Paris, France, where she focuses on the management of patients suffering from myeloid malignancies, especially chronic myeloid leukaemia (CML) and rare myeloproliferative disorders.
Dr Rea’s interests centre around clinical haematology. Besides traditional patient care, she is involved in academic and pharma-sponsored clinical trials, translational CML research, and medical education. She is the Vice President of the French Cooperative Group of CML (FI-LMC) and works with several international organizations including the European School of Hematology (ESH), ESH-International Chronic Myeloid Leukemia Foundation, The EuropeanLeukemiaNet, the Society of Hematologic Oncology, and the American Society of Hematology.
SA Pathology, Adelaide, Australia
Associate Professor Sue Branford is Head of the Leukaemia Lab in the Department of Genetics and Molecular Pathology at SA Pathology, Adelaide.
Dr Branford’s research is focused on understanding the factors that predict for response to tyrosine kinase inhibitor therapy and the mechanisms of drug resistance. She has expertise in molecular monitoring of the BCR-ABL1 gene for patients with CML. As such she is a major contributor to international collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data.
